Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Director/PDMR Shareholding

15 Sep 2011 10:04

RNS Number : 2968O
Evolution Group PLC
15 September 2011
 



The Evolution Group Plc

Notification of Transactions of Directors

 

15 September 2011

THE EVOLUTION GROUP PLC

(the "Company")

 

Notification of Transactions of Directors

 

The Evolution Group Plc 2002 Executive Share Incentive Plan

 

The Evolution Group PLC announces that the Remuneration Committee of the Company (the "Committee") has on 14 September 2011 granted call rights over 1,285,000 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") to Chief Executive, Alex Snow, under the Evolution Group Plc 2002 Executive Share Incentive Plan (the "Plan").

 

The awards, which were granted for nil consideration, have an exercise price of 1 pence per share. The awards were granted subject to performance conditions which include continued employment up to the date of exercise of call rights and achievement in aggregate of the Group's internal forecast statutory profit before tax for the three years to 31 December 2013 and will vest in July 2014. The awards also vest automatically on a change of control of the Company.

 

These awards were granted following agreement in principle by the Committee in May 2011 to provide long term incentive arrangements for the Chief Executive following the lapse of awards made in 2009 under the Plan. The awards made in 2009 were also subject to automatic vesting on change of control.

 

On 25 July 2011, the Committee agreed to enter into a commitment to make awards to Alex Snow under the Plan over 2,000,000 Ordinary Shares subject to the performance conditions set out above (including automatic vesting on change of control) once the Company was no longer in a close period. In light of the possible change of control of the Company announced on 9 September 2011, Alex Snow requested that the Committee reduce the quantum of the awards from 2,000,000 to 1,285,000 Ordinary Shares. The Committee has agreed to this request, although it has resolved to reconsider the granting of further awards in due course should a change of control not take place.

Also on 25 July 2011, the Committee agreed to enter into a commitment (once the Company was no longer in a close period) to award additional call rights over 570,000 Ordinary Shares to Alex Snow under the Plan in respect of deferral of £400,000 or four fifths of his base salary (the "Salary Deferral Awards"). Given the possible change of control of the Company, Alex Snow has requested that the Committee not make the Salary Deferral Awards. The Committee has agreed to this request and those awards will not now be granted.

Following the above transactions, Alex Snow holds the following awards under the Plan and under the 2010 Joint Share Ownership Plan )("JSOP").

Name The Plan JSOP

Alex Snow 1,838,330 2,333,333

This notification relates to disclosures made in accordance with Disclosure and Transparency Rule 3.1.4(R)(1)(a).

For more information please contact:

 

 

Pelham Bell Pottinger Tel: 020 7861 3925

Victoria Geoghegan Mob: 07917 551155

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSKELBFFKFBBBX
Date   Source Headline
25th Apr 20243:46 pmRNSChange of Name
22nd Apr 202410:11 amRNSHolding(s) in Company
11th Apr 20243:04 pmRNSHolding(s) in Company
9th Apr 20247:00 amRNSHolding(s) in Company
8th Apr 20244:03 pmRNSHolding(s) in Company
5th Apr 20243:39 pmRNSDirector/PDMR Shareholding
5th Apr 20242:40 pmRNSHolding(s) in Company
4th Apr 20241:59 pmRNSResult of General Meeting
4th Apr 20247:00 amRNSResult of Retail Offer
19th Mar 20245:03 pmRNSRetail Offer
19th Mar 20245:00 pmRNSAcquisition, Fundraising and Change of Name
27th Feb 20247:00 amRNSSFX-01 positive update in bowel cancer models
19th Feb 202411:22 amRNSPositive update on SFX-01 in vitro GBM studies
9th Feb 202411:01 amRNSNotice of Dispute lodged with Stalicla SA
16th Jan 20243:07 pmRNSSeries B Fund Raise by partner, Stalicla SA
29th Dec 202311:29 amRNSHolding(s) in Company
22nd Dec 20237:00 amRNSDirectorate Changes
13th Nov 20237:00 amRNSUpcoming conferences
31st Oct 20237:00 amRNSHalf-year Report
26th Oct 20237:00 amRNSErasmus Medical Center begins glioblastoma studies
19th Oct 20232:26 pmRNSAuthored Article Publication
5th Sep 20237:00 amRNSDirectorate Changes
15th Aug 20237:00 amRNSFinal Report from Phase 1b PK/PD study
3rd Aug 202312:38 pmRNSRule 17 Disclosure
2nd Aug 20237:00 amRNSReturn of rights to Sulforadex from Juvenescence
21st Jul 202312:02 pmRNSResult of AGM
27th Jun 20237:00 amRNSSFX-01 radiosensitisation effect confirmed in-vivo
20th Jun 20231:59 pmRNSNotice of AGM & Posting of Annual Report
19th Jun 20237:00 amRNSGrant Success for Glioblastoma studies
7th Jun 20237:00 amRNSFinal Results
26th May 202311:00 amRNSNotice of Results
22nd Mar 20237:00 amRNSPreliminary results from Phase 1b study
16th Mar 20232:00 pmRNSPrice Monitoring Extension
16th Mar 202311:05 amRNSSecond Price Monitoring Extn
16th Mar 202311:00 amRNSPrice Monitoring Extension
16th Mar 20237:00 amRNSFurther evidence of radiosensitisation by SFX-01
13th Mar 20237:00 amRNSNo exposure to Silicon Valley Bank
25th Jan 20237:00 amRNSClinical trial update
14th Dec 20225:08 pmRNSGrant of Options - Director/PDMR Shareholding
12th Dec 202211:54 amEQSEvgen Pharma 'cash runway in pretty good shape'
8th Dec 20227:00 amRNSHalf-year Report
2nd Dec 20227:00 amRNSNotice of Half Year Results
30th Nov 20222:06 pmRNSSecond Price Monitoring Extn
30th Nov 20222:00 pmRNSPrice Monitoring Extension
16th Nov 20227:00 amRNSStudy started of new SFX-01 tablet formulation
21st Oct 202211:05 amRNSSecond Price Monitoring Extn
21st Oct 202211:00 amRNSPrice Monitoring Extension
12th Oct 20224:41 pmRNSSecond Price Monitoring Extn
12th Oct 20224:35 pmRNSPrice Monitoring Extension
12th Oct 20227:00 amRNSClinical trial update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.